

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **CHANGE OF DATE OF BOARD MEETING**

Reference is made to the announcement of New Ray Medicine International Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 17 March 2022 in relation to the notice of a meeting of the board of directors of the Company (“**Board**”) proposed to be held on Tuesday, 29 March 2022 for the purposes of, among other matters, considering and approving the final results of the Group for the year ended 31 December 2021 and its publication thereof, and considering the payment of a final dividend, if any.

As additional time is required to finalise the financial results of the Group for the year ended 31 December 2021, the Board hereby announces that the Board meeting originally scheduled to be held on Tuesday, 29 March 2022 has been rescheduled to Thursday, 31 March 2022 with the same agenda as set out in the abovementioned announcement.

On behalf of the Board

**New Ray Medicine International Holding Limited**

**Wang Qiuqin**

*Chairman & Executive Director*

Hong Kong, 29 March 2022

*As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*